Abstract
Introduction: The major complications
of stent implantation are restenosis and
late stent thrombosis. PBMA polymers
are used for stent coating because of their
mechanical properties. We previously
synthesized and characterized Dextrangraft-polybutylmethacrylate copolymer
(Dex-PBMA) as a potential stent
coating. In this study, we evaluated the
haemocompatibility and biocompatibility
properties of Dex-PBMA in vitro and in
vivo.
Methods: Here, we investigated: (1)
the effectiveness of polymer coating under physiological conditions and its ability to release
Tacrolimus®, (2) the capacity of Dex-PBMA to inhibit Staphylococcus aureus adhesion, (3) the
thrombin generation and the human platelet adhesion in static and dynamic conditions, (4) the
biocompatibility properties in vitro on human endothelial colony forming cells ( ECFC) and on
mesenchymal stem cells (MSC) and in vivo in rat models, and (5) we implanted Dex-PBMA and
Dex-PBMATAC coated stents in neointimal hyperplasia restenosis rabbit model.
Results: Dex-PBMA coating efficiently prevented bacterial adhesion and release Tacrolimus®.
Dex-PBMA exhibit haemocompatibility properties under flow and ECFC and MSC compatibility.
In vivo, no pathological foreign body reaction was observed neither after intramuscular nor
intravascular aortic implantation. After Dex-PBMA and Dex-PBMATAC coated stents 30 days
implantation in a restenosis rabbit model, an endothelial cell coverage was observed and the lumen
patency was preserved.
Conclusion: Based on our findings, Dex-PBMA exhibited vascular compatibility and can
potentially be used as a coating for metallic coronary stents.